Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, pr... Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -2.07 | -24.6428571429 | 8.4 | 8.6099 | 6.0201 | 42285 | 7.41084953 | CS |
4 | -0.46 | -6.77466863034 | 6.79 | 8.6099 | 5.44 | 55366 | 6.88845271 | CS |
12 | 1.78 | 39.1208791209 | 4.55 | 19.44 | 4.06 | 620589 | 11.92589547 | CS |
26 | -2.545 | -28.676056338 | 8.875 | 19.44 | 4.06 | 303666 | 11.47470399 | CS |
52 | -18.42 | -74.4242424242 | 24.75 | 24.75 | 4.06 | 219050 | 12.13275108 | CS |
156 | -18.42 | -74.4242424242 | 24.75 | 24.75 | 4.06 | 219050 | 12.13275108 | CS |
260 | -18.42 | -74.4242424242 | 24.75 | 24.75 | 4.06 | 219050 | 12.13275108 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions